Seeking to ‘close the loop’ in drug discovery, small molecule biotech emerges from semi-stealth with investor backing

Two years after securing seed funding and remaining in a state of “semi-stealth,” a San Francisco biotech keen on combining evolution and small molecule discovery recently bagged a VC round that will let it do just that.

Known as Anagenex, the company announced Wednesday that it raised a $30 million...

Click to view original post